Purpose: We hypothesized that inhibition and trapping of PARP1 alone would be sufficient
to achieve antitumor activity. In particular, we aimed to achieve selectivity over PARP2 …

Poly-ADP-ribose-polymerase inhibitors (PARPi) are considered to be optimal tools for
specifically enhancing radiosensitivity. This effect has been shown to be replication …

The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for
potential therapeutic repurposing for non‐oncological indications. Considering (a) the …

Background The oral PARP inhibitor olaparib has shown efficacy in patients with BRCA-
mutated cancer. This Phase I, open-label, three-part study (Parts A–C) in patients with …

Olaparib is an inhibitor of poly ADP ribose polymerase 1 (PARP-1). Phase I and II trials
showed promising results of olaparib against tumours in BRCA mutation carriers. Currently …

Approximately two million fractions of radiotherapy are administered in the UK every year, as
part of adjuvant, radical or palliative cancer treatment. For many tumour types, radiotherapy …

PARP was an enzyme found in the nucleus of eukaryotic cells that played a crucial role in
repairing damaged DNA. Recently, PARP inhibitors have demonstrated great potential in …

3048 Background: We previously reported the comparative bioavailability of the capsule
(CAP) formulation of olaparib and the more convenient new tablet (TAB) formulation (Molife …

Background PARP inhibitors (PARPi) have the potential to impact cancer therapy in a
selective patient population; however, despite current patient selection methods clinical …

Purpose To summarize similarities and differences in efficacy, safety, and cost of available
PARP-inhibitors and offers pearls to distinguish subtle nuances between each agent to help …